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1109A New Score for Risk Stratification of Patients With Acute Coronary
Syndromes Undergoing Percutaneous Coronary Intervention
The ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy–
Percutaneous Coronary Intervention) Risk Score
Objectives This study sought to develop a new score speciﬁc for patients with non–ST-segment
elevation acute coronary syndromes (NSTEACS) undergoing percutaneous coronary intervention
(PCI) (the ACUITY-PCI [Acute Catheterization and Urgent Intervention Triage Strategy–Percutaneous
Coronary Intervention] risk score).
Background The TIMI (Thrombolysis In Myocardial Infarction) and GRACE (Global Registry for Acute
Coronary Events) risk scores are recommended for risk stratiﬁcation of patients with NSTEACS. How-
ever, these scores were not optimized for patients undergoing an early invasive strategy with PCI.
Methods The ACUITY-PCI risk score was created from data for 1,692 patients enrolled in the formal
angiographic substudy of the ACUITY (Acute Catheterization and Urgent Intervention Triage Strat-
egy) trial by integrating clinical, angiographic, laboratory, and electrocardiographic variables selected
by multivariable analysis. The score was subsequently validated in a different population of 846 pa-
tients and compared with the GRACE and TIMI risk scores, and the SYNTAX (Synergy Between PCI
with Taxus and Cardiac Surgery) and Clinical SYNTAX scores.
Results Six variables (2 clinical, 1 laboratory/electrocardiographic, and 3 angiographic) were included in
he ACUITY-PCI score: insulin-treated diabetes; renal insufﬁciency; baseline cardiac biomarker elevation or
T-segment deviation; bifurcation lesion; small vessel/diffuse coronary artery disease; and the extent of
oronary artery disease. Event rates increased signiﬁcantly across tertiles of ACUITY-PCI score. Compared
ith the other scores, the ACUITY-PCI score had the best discrimination (C-statistic), calibration (Hosmer-
emeshow statistic), and index of separation. Moreover, the net reclassiﬁcation improvement varied from
% to 38% and the integrated discrimination index from 1.9% to 2.7%.
onclusions The ACUITY-PCI risk score is a new tool integrating clinical, angiographic, and labora-
tory/electrocardiographic variables speciﬁcally developed for patients with NSTEACS undergoing PCI.
This score displayed better prognostic accuracy in terms of discrimination and calibration than other
currently available scores for risk stratiﬁcation of patients with NSTEACS. (Comparison of Angiomax
Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158) (J Am Coll Cardiol Intv 2012;5:
1108–16) © 2012 by the American College of Cardiology FoundationL
B
rPatients with non–ST-segment elevation acute coronary syn-
dromes (NSTEACS) have a wide range of risk for morbidity
and mortality according to their baseline risk factors, clinical
syndrome acuity, and management strategy. Prospective risk
stratification is essential to estimate patient prognosis and aid
in clinical decision making. Current guidelines for the man-
agement of patients with NSTEACS recommend the use of
the TIMI (Thrombolysis In Myocardial Infarction) risk score
or the GRACE (Global Registry for Acute Coronary Events)
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Research Group, Yale University School of Medicine, New Haven, Connecticut. The
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is a consultant for Abbott, Regado, Ortho McNeal, Janssen, Merck, Maya Medical, and
straZeneca; and has received a research grant from Sanofi/Bristol-Myers Squibb, Eli Mscore for risk stratification of patients with NSTEACS (1,2).
These scores integrate several clinical, electrocardiographic,
and cardiac biomarker variables, but they do not include
angiographic variables and have not been optimized for pa-
tients undergoing percutaneous coronary intervention (PCI).
Recent studies have reported that angiographic variables
contribute incremental prognostic information for risk strat-
ification of patients with NSTEACS (3). The purely an-
giographic SYNTAX (Synergy Between PCI With Taxus
illy, and Daiichi Sankyo. Dr. Stone has served as a consultant to Abbott Vascular,
oston Scientific, Medtronic, and The Medicines Company. All other authors have
eported that they have no relationships relevant to the contents of this paper to disclose.anuscript received June 1, 2012, accepted July 25, 2012.
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1110and Cardiac Surgery) score has also shown to be an
independent predictor of mortality, myocardial infarction
(MI), and target vessel revascularization in patients with
NSTEACS undergoing PCI (4). However, the SYNTAX
score was not developed from a derivation cohort in
NSTEACS with subsequent validation in a test cohort, but
it was based on an arbitrary ranking of lesion complexity (5)
and does not include clinical or other baseline variables. For
these reasons, we sought to develop a new risk score
integrating clinical, angiographic, laboratory, and electro-
cardiographic variables for risk assessment of 1-year mor-
tality and MI in patients with NSTEACS undergoing PCI
in the large multicenter, prospective randomized ACUITY
(Acute Catheterization and Urgent Intervention Triage
Strategy) trial. Moreover, the prognostic accuracy of this
new score (the ACUITY-PCI risk score) was compared
with that of currently available
score systems for risk stratification
of patients with NSTEACS.
Methods
Study protocol. The ACUITY trial
design has been previously repor-
ted in detail (6). Briefly, ACUITY
was a large, international, multi-
center, prospective randomized trial
of patients with moderate- and
high-risk NSTEACS undergoing
an early invasive strategy. Patients
were randomly assigned before cor-
onary angiography to heparin (un-
fractionated or enoxaparin) plus a
glycoprotein IIb/IIIa inhibitor, bi-
valirudin plus a glycoprotein IIb/
IIIa inhibitor, or bivalirudin mono-
therapy. Coronary angiography was
performed in all patients within
72 h of randomization, after which
atients were treated with PCI, coronary artery bypass graft
CABG) or medical therapy at the physician’s discretion. All
ajor adverse events observed during the study were adjudicated
y an independent clinical events committee blinded to treatment
ssignment. The study protocol was approved by the institutional
eview board or ethics committee at each center, and written
nformed consent was obtained in all patients.
Objectives, study population, and deﬁnitions. The objective
of this study was to develop and validate a new score integrat-
ing clinical, angiographic, laboratory, and electrocardiographic
variables for risk prediction of 1-year death or MI in patients
with NSTEACS and native coronary artery disease undergo-
ing PCI. The prognostic accuracy of this new score was then
compared with the SYNTAX score (5), Clinical SYNTAX
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
HR  hazard ratio
IDI  integrated
discrimination index
IoS  index of separation
MI  myocardial infarction
NRI  net reclassification
improvement
NSTEACS  non–ST-segment
elevation acute coronary
syndromes
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
TIMI  Thrombolysis In
Myocardial Infarctioncore (7), TIMI score (8), and GRACE score (2) in terms of ciscrimination (9), calibration (10), index of separation (IoS)
1), net reclassification improvement (NRI), and integrated
iscrimination index (IDI) (1,11). The score was created and
hen validated in different cohorts of patients included in the
ormal angiographic substudy of the ACUITY trial. Quanti-
ative coronary angiography (QCA) was performed as previ-
usly described (12) by experienced core angiographic labora-
ory technicians (Cardiovascular Research Foundation, New
ork, New York) blinded to treatment assignment and clinical
utcomes.
The SYNTAX score and the Clinical SYNTAX score were
alculated as previously described (4). The extent of coronary
rtery disease was defined as the sum of the lengths of all
esions in the coronary tree with 30% diameter stenosis in
essels with a reference diameter 1.5 mm determined by
CA. To determine this variable, QCA was performed of the
ntire coronary tree, and all lesions with 30% diameter
tenosis were identified. As defined for the SYNTAX score,
mall vessel/diffuse coronary artery disease was considered
resent when at least 75% of the length of any segment
roximal to the lesion, at the site of the lesion or distal to the
esion had a vessel diameter of2 mm (5). The jeopardy score
as defined as previously described (13). Renal insufficiency
as defined as a calculated creatinine clearance of60 ml/min
etermined by the Cockcroft-Gault equation.
Statistical analysis and score determination. Continuous
data are presented as mean  SD and were compared using the
tudent t test. Categorical variables were summarized as counts
nd percentages and were compared by chi-square test or Fisher
xact test as appropriate. Correlations between angiographic and
linical variables included in the score were assessed by the Pearson
est. The ACUITY-PCI risk score was created by fitting clinical,
ngiographic, laboratory, and electrocardiographic variables into a
ox multivariable analysis for risk prediction of 1-year death or
I. To not exclude variables potentially correlated with the
utcome, univariable selection was performed setting the entry
riteria at p  0.1. The multivariable model was then built by
tepwise variable selection with same entry and exit criteria as in
he univariable analysis. The following variables were considered:
ll variables included in the SYNTAX score (total occlusion,
rifurcation, bifurcation, aorto-ostial lesion, severe tortuosity,
ength 20 mm, heavy calcification, thrombus, small vessel/
iffuse coronary artery disease); pre- and post-procedural
IMI flow; jeopardy score; the extent of coronary artery
isease (per 10-mm increment of lesions 30%); age; sex;
iabetes; renal insufficiency; prior MI; prior PCI; baseline
ardiac biomarker elevation; or ST-segment deviation1 mm.
he score was then formulated by attributing integer numbers
o the variables retained in the multivariable model. The
ariable with the smallest estimated coefficient was attributed 1
oint and was considered as the baseline variable. The score of
he other variables were determined by dividing their estimated
oefficients by the coefficient of the baseline variable. Multi-
ollinearity between variables was assessed using the variance
o
p
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1111inflation factor. The simple random sampling method Proc
Surveyselect (SAS, SAS Institute, Cary, North Carolina) was
used to randomly assign patients to the derivation or validation
cohort with 2:1 sample ratio. One-year outcomes were deter-
mined using Kaplan-Meier methodology and compared using
the log-rank test.
Discrimination and calibration were determined by the
C-statistic and the Hosmer-Lemeshow goodness-of-fit
test, respectively (9,10). Differences in discrimination
power between the ACUITY-PCI score and the 4 other
scores (TIMI and GRACE scores, SYNTAX and Clin-
ical SYNTAX scores) were evaluated using the chi-square
test. The intrinsic prognostic information of each score was
assessed by the IoS, which is the difference between the
predicted probability of an event for a patient in the group
with the worst prognosis and the predicted probability of an
event for a patient in the group with the best prognosis (1).
Prognostic accuracy of each score was further assessed by
IDI, which is a measure of how well the model improves the
integrated sensitivity without sacrificing integrated specific-
ity, and the NRI, which is a measure of how well a model
correctly reclassifies predicted probabilities (1,11). Statistical
analyses were performed using SAS (version 9.2, SAS
Institute, Cary, North Carolina). We considered p values
0.05 statistically significant.
Results
The flow diagram of the study is shown in Figure 1. QCA
was performed in 6,921 patients enrolled in the ACUITY
trial angiographic substudy, including 3,826 patients who
underwent PCI. After excluding patients with prior CABG
Figure 1. Flow Diagram of the Study
The angiographic substudy of the ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) trial enrolled 6,921 patients, 2,538 of
whom were included in the present study (1,692 in the derivation cohort
and 846 in the validation cohort). PCI  percutaneous coronary interven-d
tion; QCA  quantitative coronary angiography.(n  862) and those for whom all angiographic (n  337)
r clinical (n  89) variables were not available, 2,538
atients remained for the present analysis. The score was
Table 1. Baseline Clinical Characteristics of Patients in the Derivation
and Validation Cohorts
Score Derivation
Cohort
(n  1,692)
Score Validation
Cohort
(n  846) p Value
Age, yrs 60.4 11.7 61.3 11.7 0.08
Male 67.0 (1,134/1,692) 68.6 (580/846) 0.44
Hypertension 66.3 (1,118/1,687) 63.8 (538/843) 0.23
Diabetes mellitus 29.4 (494/1,682) 25.9 (218/843) 0.07
Insulin-treated 8.6 (144/1,682) 5.8 (49/843) 0.01
Hypercholesterolemia 56.2 (937/1,666) 55.6 (464/835) 0.77
Current smoker 35.0 (589/1,685) 36.0 (304/845) 0.63
Prior myocardial infarction 30.2 (501/1,660) 27.4 (227/827) 0.16
Prior PCI 43.5 (735/1,691) 45.1 (381/844) 0.44
Renal dysfunction 14.8 (235/1,583) 16.5 (131/795) 0.31
Baseline cardiac biomarker
elevation
61.1 (968/1,584) 58.1 (456/785) 0.17
ST-segment deviation 1 mm 25.0 (423/1,692) 25.4 (215/846) 0.85
SYNTAX score 11.6 8.5 11.3 7.9 0.88
Clinical SYNTAX score 13.1 14.2 12.3 10.9 0.20
GRACE score 79.5 29.4 80.4 29.5 0.43
TIMI risk score
Low (0–2) 15.8 (219/1,383) 17.5 (118/676) 0.37
Intermediate (3–4) 59.0 (816/1,383) 59.5 (402/676) 0.85
High (5–7) 25.2 (348/1,383) 23.1 (156/676) 0.33
Left ventricular ejection
fraction, %
53.4 11.6 53.9 11.1 0.28
Number of diseased vessels 1.58 0.72 1.52 0.67 0.08
Multivessel disease 45.2 (765/1,692) 43.1 (365/846) 0.33
LAD disease 58.7 (994/1,692) 56.4 (477/846) 0.27
LCX disease 44.4 (752/1,692) 45.4 (384/846) 0.67
RCA disease 54.5 (921/1,692) 50.7 (429/846) 0.08
Left main disease 0.9 (15/1,692) 1.2 (10/846) 0.52
Extent of disease per patient* 40.15 25.56 40.31 27.57 0.89
Jeopardy score 2.60 2.36 2.71 2.37 0.26
Total number of DES 1.10 0.72 1.13 0.68 0.34
Total number of BMS 0.17 0.41 0.13 0.39 0.06
Ostial lesion 2.8 (48/1,692) 2.6 (22/846) 0.80
Lesion length, mm 15.8 10.3 15.4 9.8 0.35
Lesion length 20 mm 44.0 (745/1,692) 42.1 (356/846) 0.37
Severe tortuosity 8.1 (137/1,692) 9.7 (82/846) 0.18
Thrombus 21.7 (368/1,692) 18.6 (157/846) 0.26
Severe calciﬁcation 6.7 (113/1,692) 7.2 (61/846) 0.62
Bifurcation 41.1 (695/1,692) 40.8 (345/846) 0.90
Treated 31.2 (528/1,692) 31.2 (264/846) 0.96
Trifurcation 2.1 (36/1,692) 1.5 (13/846) 0.36
Total occlusion 20.6 (348/1,692) 20.4 (173/846) 0.96
Values are mean SD or % (n/N). *Expressed in millimeters.
BMS  bare-metal stent(s); DES  drug-eluting stent(s); GRACE  Global Registry for Acute
Coronary Events; LAD  left anterior descending; LCX  left circumflex; PCI  percutaneous
coronary intervention; RCA right coronary artery; SYNTAX Synergy Between PCI With Taxus
and Cardiac Surgery; TIMI Thrombolysis In Myocardial Infarction.erived from data for 1,692 randomly selected patients and
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1112subsequently validated in the remaining 846 patients. As
shown in Table 1, no significant differences in the baseline
clinical characteristics were apparent between patients in the
derivation and validation cohorts, except for insulin-treated
diabetes, which was more frequent in the validation cohort.
Similarly, no significant differences in 30-day or 1-year clinical
outcomes were apparent between the 2 groups (Table 2).
The ACUITY-PCI risk score. As shown in Table 3, after
univariable and multivariable selection, 2 clinical, 3 angio-
graphic, and 1 laboratory/electrocardiographic variables re-
mained significantly associated with the risk of 1-year death
Table 2. 30-Day and 1-Year Clinical Outcomes in Patients in the Score
Derivation and in the Score Validation Cohorts
Score Derivation
Cohort
(n  1,692)
Score Validation
Cohort
(n  846) p Value
30-day clinical outcomes
Death 0.8 (13) 1.1 (9) 0.45
Cardiac 0.7 (11) 1.0 (8) 0.42
Reinfarction 6.8 (115) 7.1 (60) 0.78
Q-wave 1.0 (17) 1.4 (12) 0.36
Non–Q-wave 5.8 (98) 5.7 (48) 0.90
Death or reinfarction 7.3 (123) 7.8 (66) 0.64
Non-CABG–related major
bleeding
5.9 (100) 7.4 (62) 0.17
CABG-related major bleeding 0.8 (14) 0.6 (5) 0.51
Target vessel revascularization 2.5 (42) 1.8 (15) 0.26
1-year clinical outcomes
Death 2.3 (38) 2.6 (21) 0.72
Cardiac 1.2 (20) 1.4 (12) 0.62
Reinfarction 9.0 (149) 9.3 (78) 0.74
Q-wave 1.4 (23) 2.2 (18) 0.15
Non–Q-wave 7.6 (126) 7.3 (61) 0.83
Death or reinfarction 10.5 (173) 11.0 (92) 0.63
Target vessel revascularization 7.7 (124) 8.6 (66) 0.70
Values are % (n).
CABGcoronary artery bypass graft.
Table 3. Independent Predictors of 1-Year Death and
Derivation Dataset
Coefficien
Extent of coronary disease (1 point for each
10 mm of disease)
0.057
Small vessel/diffuse coronary artery disease* 0.132
Bifurcation lesion present 0.228
Baseline cardiac biomarker elevation or
ST-segment deviation
0.463
Insulin-treated diabetes 0.675
Renal insufﬁciency† 0.712
Multicollinearity is present in the model when the VIF is10. *Defined
60 ml/min determined by the Cockcroft-Gault equation.
ACUITYAcute Catheterization and Urgent Intervention Triage StraSYNTAX Synergy Between PCI With Taxus and Cardiac Surgery; VIF varianor MI. The scores attributed to each variable according to
their estimated coefficients from the derivation dataset are
shown in Table 3. Minimal correlation was apparent be-
tween these variables (Online Table 1), demonstrating that
each retained variable provides unique prognostic utility.
Moreover, the variance inflation factor showed absence of
multicollinearity among variables in the model (Table 3). The
C-statistic for this model was 0.67 (95% confidence interval
[CI]: 0.62 to 0.72); the chi-square statistic for calibration was
7.13 (p 0.52); and the IoS was 0.44. The range of each tertile
and the frequency distribution of each variable across tertiles of
ACUITY-PCI score are displayed in Online Table 2. As
shown in Figure 2A, event rates in the derivation cohort
increased significantly across tertiles of ACUITY-PCI score:
5.3% in the lower tertile; 9.1% in the middle tertile; and 19.0%
in the upper tertile (p 0.001). The hazard ratio (HR) of the
1-year composite rate of death or MI was 2.02 (95% CI: 1.21
to 3.36) for tertile III versus tertile II, 3.88 (95% CI: 2.13 to
7.06) for tertile III versus tertile I, and 1.88 (95% CI: 0.96 to
3.67) for tertile II versus tertile I.
For the 846 patients included in the validation cohort, the
ACUITY-PCI score displayed good prognostic accuracy with
a C-statistic of 0.70 (95% CI: 0.61 to 0.73), a chi-square
statistic for calibration of 6.2 (p 0.62), and an IoS of 0.42. As
shown in Figure 2B, event rates in the validation cohort
increased significantly across tertiles of ACUITY-PCI score:
5.1% in the lower tertile; 9.3% in the middle tertile; and
18.6% in the upper tertile (p  0.001). In addition, the
CUITY-PCI score displayed good prognostic accuracy
C-statistic  0.72, p  0.0001) and was an independent
redictor (HR: 1.09, 95% CI: 1.02 to 1.16, p  0.008) of
he 1-year risk of definite/probable stent thrombosis.
Statistical performance of 5 varying risk scores. Score per-
formances in the validation cohort are shown in Table 4.
Among the 5 scores, the ACUITY-PCI score displayed the
best discrimination (p  0.0001), the best calibration, and
the best IoS. Moreover, the NRI varied from 9% to 36% and
ontributing to the ACUITY-PCI Score From the
Hazard Ratio
95% Confidence Interval) VIF p Value Score
1.06 (1.00–1.12) 1.07 0.03 1
1.14 (1.02–1.28) 1.04 0.03 2
1.26 (1.01–1.57) 1.05 0.04 4
1.59 (1.09–2.30) 1.01 0.01 8
1.96 (1.27–3.04) 1.01 0.002 12
2.04 (1.43–2.90) 1.00 0.0001 12
he SYNTAX score (5). †Defined as a calculated creatinine clearance of
Imyocardial infarction; PCI percutaneous coronary intervention;MI C
t (
as for t
tegy; Mce inflation factor.
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1113the IDI from 1.9% to 2.7%. As shown in Figure 3, the
ACUITY-PCI score was the only one to display both good
discrimination and good calibration. Clinical scores (TIMI
and GRACE) were reasonably well calibrated, but they
displayed poor discrimination, whereas the SYNTAX score
and the Clinical SYNTAX score displayed fair discrimina-
tion, but less than optimal calibration.
Antithrombotic therapy and the ACUITY-PCI score. Clinical
utcomes of patients treated with heparin plus a glyco-
rotein IIb/IIIa inhibitor or bivalirudin plus a glycoprotein
Ib/IIIa inhibitor versus bivalirudin monotherapy, stratified
y tertiles of the ACUITY-PCI sore are shown in Figure 4.
n the entire patient cohort (n  2,538), no significant
Figure 2. Kaplan-Meier Curves Showing Cumulative Rates of 1-Year Death
or MI Across Tertiles of ACUITY-PCI Score
(A) The derivation dataset. (B) The validation dataset. Signiﬁcant differ-
ences in the cumulative rate of death/myocardial infarction (MI) were
apparent across tertiles of ACUITY-PCI score, in both the derivation and
validation datasets. Abbreviations as in Figure 1.ifference in the 1-year risk of death or MI was apparentetween the 2 treatment groups across tertiles of the
CUITY-PCI score.
iscussion
The main findings from the present study are as follows.
1) A novel prognostic scoring system (the ACUITY-PCI
risk score) consisting of 6 readily available variables has been
developed that is able to accurately predict the 1-year rates
of death or MI in patients with NSTEACS in whom
coronary intervention is performed. 2) The 6 variables
independently predictive of adverse outcomes included 2
clinical variables (insulin-treated diabetes and renal insuffi-
ciency), 1 laboratory/electrocardiographic variable (baseline
cardiac biomarker elevation or ST-segment deviation), and
3 angiographic variables (bifurcation lesion, small vessel/diffuse
coronary artery disease, and the extent of coronary artery
disease). 3) In the validation cohort, the ACUITY-PCI score
displayed good discrimination and calibration, with 1-year
event rates increasing more than 3-fold across tertiles of this
risk score. 4) When compared with the TIMI and GRACE
scores, and the SYNTAX and Clinical SYNTAX scores, the
ACUITY-PCI score displayed the best accuracy in terms of
discrimination, calibration, and IoS, with the NRI varying
from 9% to 36% and IDI from 1.9% to 2.7%.
The ACUITY-PCI risk score was created specifically for
patients with NSTEACS undergoing PCI. In this regard,
although the TIMI and the GRACE scores have been
shown to be valuable prognostic tools at the time of hospital
admission for selecting pharmacological strategies and iden-
tifying those patients most likely to benefit from an invasive
strategy (1,2,14), they have not been optimized for patients
undergoing PCI and, thus, have relatively poor prognostic
power to further risk stratify acute coronary syndrome
patients undergoing PCI. The ACUITY-PCI score is
therefore intended to supplement the TIMI and GRACE
scores when an invasive strategy has been undertaken and
PCI is being considered. The present study demonstrates
that angiographic variables (which only become available
after initial cardiac catheterization and, thus, are not avail-
able in the TIMI and GRACE scores) add important
independent information to risk stratify NSTEACS pa-
tients undergoing PCI. In support of this concept, we have
previously demonstrated that the SYNTAX score, a purely
angiographic measure highly different from the ACUITY-
PCI score (which combines clinical, laboratory, and angio-
graphic variables), is by itself an independent predictor of
the occurrence of death, MI, and target vessel revascular-
ization at 1 year in this same high-risk group of patients (4).
In the present study, we have shown that combining
select angiographic measures with clinical, electrocardio-
graphic, and laboratory variables (in the ACUITY-PCI
score) results in greater predictive accuracy and discrim-
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score or pre-angiographic TIMI and GRACE scores.
The observation that the total burden of coronary ath-
erosclerosis, as reflected by the extent of coronary artery
disease and the presence of small vessel/diffuse coronary
disease, was prognostically more powerful than descriptors
of focal lesion pathology, such as the presence of a total
occlusion, heavy calcification, thrombus, or aorto-ostial
lesion bears comment. The prognostic relevance of the
global burden of atherosclerotic disease has been recently
underscored by the PROSPECT (Predictors of Response to
CRT) study, a prospective evaluation of the natural history of
coronary artery atherosclerosis in patients with acute coronary
syndromes (15). In that study, major adverse cardiovascular
events during 3-year follow-up were equally distributed be-
tween recurrence at the site of treated culprit lesions (those
responsible for the initial clinical syndrome) and to untreated
nonculprit lesions, most of which were angiographically mild at
baseline (mean diameter stenosis: 32.3  20.6%).
The clinical variables incorporated in the ACUITY-PCI
score were insulin-treated diabetes and renal insufficiency.
Patients with diabetes and renal insufficiency have more
Figure 3. Discrimination (C-Statistic) and Calibration (Hosmer-Lemeshow
Test) for the 5 Scores
Compared with the other scores, the ACUITY-PCI score (validation dataset)
displayed the best discrimination and calibration. GRACE  Global Registry
for Acute Coronary Events; TIMI  Thrombolysis In Myocardial Infarction;
Table 4. Prognostic Accuracy of Risk Scores in Acute Coronary Syndromes
ACUITY-PCI Score* GRACE
C-statistic (95% CI) 0.70 (0.62–0.76) 0.51 (0.42
HL statistic, p value 0.62 0.2
Index of separation 0.42 0.0
Net reclassiﬁcation improvement, %† — 24
Integrated discrimination index, %† — 2.7
*Validation dataset. †In relation to the ACUITY-PCI score.
CI confidence interval; HL Hosmer-Lemeshow; other abbreviations as in Table 1.other abbreviations as in Figure 1.extensive and complex coronary artery disease, which is
often deemed responsible for the adverse prognosis of these
patients (16–18). It is noteworthy that in our analysis,
insulin-treated diabetes and renal insufficiency were not
significantly correlated with the angiographic factors that
were retained in the prognostic ACUITY-PCI score.
Moreover, insulin-treated diabetes and renal insufficiency
remained independent predictors of adverse events after
PCI, even after correcting for these angiographic variables,
suggesting that other factors, such as elevated platelet
reactivity, poor response to thienopyridines, and/or bleeding
propensity may contribute to the poor prognosis in patients
with diabetes and chronic kidney disease (19–21).
Not only was the ACUITY-PCI risk score more prog-
nostically accurate than the other scores examined, but with
only 6 variables, the ACUITY-PCI score is simple to
calculate. Compared with the SYNTAX score, only 3
angiographic variables are required. It is important to
underscore that the presence of any bifurcation lesion
(as classified by the Medina score) is included when determin-
ing the ACUITY-PCI score, whether treated or not. How-
ever, the ACUITY-PCI score does not require any further
detailing of the bifurcation lesion, as opposed to the SYNTAX
score in which the exact Medina classification of the bifurca-
tion is an integral component (22). This simplification may
translate into better reproducibility of the ACUITY-PCI score
than the SYNTAX score, for which substantial inter- and
intraobserver variability has been reported (23–25).
There may be several important clinical applications of
the ACUITY-PCI risk score. Whereas bivalirudin alone
and heparin plus a glycoprotein IIb/IIIa inhibitor have
equivalent results across the risk spectrum identified by the
ACUITY-PCI risk score, this score does identify a group of
patients with an ongoing high rate of adverse ischemic
events with either of these 2 therapies. Identification of such
high-risk acute coronary syndrome patients with a poor
projected prognosis after PCI might result in preferential
referral to CABG, or the selective use of more potent anti-
platelet agents, such as prasugrel or ticagrelor, which signifi-
cantly reduce adverse ischemic events (26). Future studies are
required to confirm these approaches. Nonetheless, implemen-
TIMI Score SYNTAX Score Clinical SYNTAX Score
0.56 (0.48–0.64) 0.63 (0.56–0.71) 0.65 (0.57–0.71)
0.59 0.10 0.001
0.11 0.23 0.37
38 9 36
2.4 1.9 2.2Score
–0.59)
6
6tation of the most accurate risk stratification tools is important
r; HEP
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patients about their risk of future events.
Study limitations. The ACUITY-PCI score was developed in
patients enrolled in the ACUITY trial. Thus, although the
discrimination of the ACUITY-PCI score was confirmed in a
distinct cohort of patients from ACUITY, its predictive accuracy
in NSTEACS patients undergoing early PCI should be further
validated from a different study dataset and from real-world
registry studies. Of note, however, neither the TIMI nor
GRACE scores, which are now universally accepted, were exter-
nally validated upon their introduction (2,8). Subsequent reports
in different cohorts of patients validated the prognostic accuracy of
these scores before they were implemented in clinical practice
(27,28). The extent of coronary artery disease was determined by
QCA, and the 30% diameter stenosis cutoff was arbitrarily
selected, which roughly correlates with a visually estimated diam-
eter stenosis of approximately 40% to 50%. Although QCA may
be time-consuming and/or not immediately available, it provides a
more objective determination of the extent and severity of coro-
nary artery disease than visual assessment does (29); therefore,
scores that use QCA may be more reproducible than those based
only on visual estimation of angiographic variables (24). Recently,
a new score specific for patients undergoing PCI, the NCDR
(National Cardiovascular Data Registry) Cath-PCI score, has
been described (30). However, as some variables used in that score
were not systematically collected in the ACUITY trial, we could
Figure 4. Kaplan-Meier Curves Showing Cumulative Rates of 1-Year Death
in the Tertiles of the ACUITY-PCI Score
No signiﬁcant difference between the 2 antithrombotic treatments was appare
BIV  bivalirudin; CI  conﬁdence interval; GPI  glycoprotein IIb/IIIa inhibitonot determine its relative prognostic accuracy. The 3 cohorts ofpatients in whom the comparative efficacy of the randomized
antithrombotic regimens was evaluated in relation to the
ACUITY-PCI score may not have been large enough to detect
modest differences in clinical outcomes. Patients with prior
CABG were excluded from the present study. As the natural
history and progression of coronary artery disease is affected by
interactions between bypass graft conduits and grafted coronary
arteries, we believe that they should be considered as a separate
group. Different variables were associated with the primary out-
come measure in the present study than in previous reports from
the ACUITY trial (3,31). These differences may be explained by
inclusion in this study of new variables with greater predictive
power, as well as evaluation of different endpoints, patient cohorts,
and time points for the primary outcome measure.
Conclusions
The ACUITY-PCI risk score is a novel and simple-to-
calculate prognostic tool specifically developed for patients
with NSTEACS undergoing PCI, which integrates clinical,
angiographic, laboratory, and electrocardiographic variables
for risk prediction of 1-year death or MI. Compared with
other available scores, the ACUITY-PCI risk score displays
the best predictive accuracy in terms of both discrimination
in Patients Treated With HEP or BIV Plus a GPI Versus BIV Monotherapy,
oss upper, middle, and lower tertiles of the ACUITY-PCI score.
 heparin; HR  hazard ratio; other abbreviations as in Figures 1 and 2.or MI
nt acrand calibration.
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